IL2 and leukemia: This is based on the results of a Swedish study of 320 patients with AML in CR randomized to IL-2/HDC or observation which improved leukemia-free survival (LFS), especially in those in CR1 where 3-year LFS was 40% in the IL-2/HDC arm and 26% in the observation arm (68).